-

Orthofix to Report First Quarter 2025 Financial Results

Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com.

Internet Posting of Information

Orthofix routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.

About Orthofix

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. To learn more, visit Orthofix.com and follow on LinkedIn.

Contacts

Investor and Media Relations

Julie Dewey, IRC
Chief Investor Relations & Communications Officer
JulieDewey@Orthofix.com
209.613.6945

Orthofix Medical Inc.

NASDAQ:OFIX

Release Versions

Contacts

Investor and Media Relations

Julie Dewey, IRC
Chief Investor Relations & Communications Officer
JulieDewey@Orthofix.com
209.613.6945

More News From Orthofix Medical Inc.

Orthofix Reports First Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6-C™ and M6-L™ artificial disc product...

Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT...

Orthofix Announces Appointment of Vickie Capps to Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously...
Back to Newsroom